Targeting a cell state common to triple-negative breast cancers

Molecular Systems Biology

Volumn 11, Issue 2, 2015, Pages

  Muellner, Markus K ^a   Mair, Barbara ^a   Ibrahim, Yasir ^b   Kerzendorfer, Claudia ^a   Lechtermann, Hannelore ^a   Trefzer, Claudia ^a   Klepsch, Freya ^a   Müller, André C ^a   Leitner, Ernestine ^a   Macho Maschler, Sabine ^c   Superti Furga, Giulio ^a   Bennett, Keiryn L ^a   Baselga, José ^d   Rix, Uwe ^e   Kubicek, Stefan ^a   Colinge, Jacques ^a   Serra, Violeta ^b   Nijman, Sebastian M B ^a  

^a ERICH SCHMID INSTITUTE OF MATERIALS SCIENCE   (Austria)

^b VALL D HEBRON UNIVERSITY HOSPITAL   (Spain)

^c UNIVERSITY OF VETERINARY MEDICINE   (Austria)

^d MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^e H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

Author keywords

breast cancer; cell state; small molecule screen

Indexed keywords

1 CYCLOPROPYL 3 [3 (5 MORPHOLINOMETHYL 1H BENZIMIDAZOL 2 YL) 1H PYRAZOL 4 YL]UREA; CRYSTAL VIOLET; FOSTAMATINIB; MASITINIB; MIDOSTAURIN; OSI 930; RUBOXISTAURIN; STAT3 PROTEIN; SUNITINIB; TANDUTINIB; TOZASERTIB; TRANSFORMING GROWTH FACTOR BETA; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; PROTEIN KINASE SYK; PROTEIN TYROSINE KINASE; SIGNAL PEPTIDE; STAT3 PROTEIN, HUMAN; STAUROSPORINE; SYK PROTEIN, HUMAN; SYK PROTEIN, MOUSE;

AFFINITY CHROMATOGRAPHY; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; BASAL LIKE BREAST CANCER; CANCER GRAFT; CELL VIABILITY; CONTROLLED STUDY; DOWN REGULATION; DRUG MECHANISM; DRUG SENSITIVITY; DRUG SENSITIZATION; DRUG SPECIFICITY; DRUG SYNTHESIS; EPIGENETICS; FEMALE; GENETIC SCREENING; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; IN VITRO STUDY; IN VIVO STUDY; LONG TERM CARE; MOLECULAR DOCKING; MOUSE; MUTATION; NONHUMAN; PHASE 1 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROTEOMICS; QUANTITATIVE ANALYSIS; RNA SEQUENCE; SIGNAL TRANSDUCTION; STRUCTURE ACTIVITY RELATION; SYNTHESIS; TARGET CELL; TRIPLE NEGATIVE BREAST CANCER; TUMOR GROWTH; TUMOR VOLUME; WESTERN BLOTTING; ANALOGS AND DERIVATIVES; ANIMAL; CELL DIFFERENTIATION; CELL PROLIFERATION; CELL SURVIVAL; DRUG DELIVERY SYSTEM; DRUG EFFECTS; DRUG SCREENING; GENE EXPRESSION PROFILING; GENETICS; METABOLISM; MOLECULARLY TARGETED THERAPY; PROCEDURES; PROTEIN DOMAIN; SEQUENCE ANALYSIS; TUMOR CELL LINE;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; CELL DIFFERENTIATION; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; DRUG DELIVERY SYSTEMS; FEMALE; GENE EXPRESSION PROFILING; HUMANS; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; MICE; MOLECULAR DOCKING SIMULATION; MOLECULAR TARGETED THERAPY; PROTEIN INTERACTION DOMAINS AND MOTIFS; PROTEIN-TYROSINE KINASES; PROTEOMICS; SEQUENCE ANALYSIS, RNA; SIGNAL TRANSDUCTION; STAT3 TRANSCRIPTION FACTOR; STAUROSPORINE; SYK KINASE; TRANSFORMING GROWTH FACTOR BETA; TRIPLE NEGATIVE BREAST NEOPLASMS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84923651864     PISSN: None     EISSN: 17444292     Source Type: Journal    
DOI: 10.15252/msb.20145664     Document Type: Article

References (55)

1. Armanious H, Gelebart P, Mackey J, Ma Y, Lai R, (2010) STAT3 upregulates the protein expression and transcriptional activity of beta-catenin in breast cancer. Int J Clin Exp Pathol 3: 654-664
2. Atwell S, Adams JM, Badger J, Buchanan MD, Feil IK, Froning KJ, Gao X, Hendle J, Keegan K, Leon BC, Muller-Dieckmann HJ, Nienaber VL, Noland BW, Post K, Rajashankar KR, Ramos A, Russell M, Burley SK, Buchanan SG, (2004) A novel mode of Gleevec binding is revealed by the structure of spleen tyrosine kinase. J Biol Chem 279: 55827-55832
3. Bernstein FC, Koetzle TF, Williams GJ, Meyer EF Jr, Brice MD, Rodgers JR, Kennard O, Shimanouchi T, Tasumi M, (1977) The Protein Data Bank: a computer-based archival file for macromolecular structures. J Mol Biol 112: 535-542
4. Bliss WL, (1939) Early man in western and northwestern Canada. Science 89: 365-366
5. Borgdorff V, Rix U, Winter GE, Gridling M, Muller AC, Breitwieser FP, Wagner C, Colinge J, Bennett KL, Superti-Furga G, Wagner SN, (2014) A chemical biology approach identifies AMPK as a modulator of melanoma oncogene MITF. Oncogene 33: 2531-2539
6. Bromberg JF, Wrzeszczynska MH, Devgan G, Zhao Y, Pestell RG, Albanese C, Darnell JE Jr, (1999) Stat3 as an oncogene. Cell 98: 295-303
7. Buettner R, Mora LB, Jove R, (2002) Activated STAT signaling in human tumors provides novel molecular targets for therapeutic intervention. Clin Cancer Res 8: 945-954
8. Burkard TR, Rix U, Breitwieser FP, Superti-Furga G, Colinge J, (2010) A computational approach to analyze the mechanism of action of the kinase inhibitor bafetinib. PLoS Comput Biol 6: e1001001
9. Carey L, Winer E, Viale G, Cameron D, Gianni L, (2010) Triple-negative breast cancer: disease entity or title of convenience? Nat Rev Clin Oncol 7: 683-692
10. Chapman RS, Lourenco PC, Tonner E, Flint DJ, Selbert S, Takeda K, Akira S, Clarke AR, Watson CJ, (1999) Suppression of epithelial apoptosis and delayed mammary gland involution in mice with a conditional knockout of Stat3. Genes Dev 13: 2604-2616
11. Colinge J, Rix U, Bennett KL, Superti-Furga G, (2012) Systems biology analysis of protein-drug interactions. Proteomics Clin Appl 6: 102-116
12. Coopman PJ, Do MT, Barth M, Bowden ET, Hayes AJ, Basyuk E, Blancato JK, Vezza PR, McLeskey SW, Mangeat PH, Mueller SC, (2000) The Syk tyrosine kinase suppresses malignant growth of human breast cancer cells. Nature 406: 742-747
13. Coxon A, Bush T, Saffran D, Kaufman S, Belmontes B, Rex K, Hughes P, Caenepeel S, Rottman JB, Tasker A, Patel V, Kendall R, Radinsky R, Polverino A, (2009) Broad antitumor activity in breast cancer xenografts by motesanib, a highly selective, oral inhibitor of vascular endothelial growth factor, platelet-derived growth factor, and Kit receptors. Clin Cancer Res 15: 110-118
14. Curtis C, Shah SP, Chin SF, Turashvili G, Rueda OM, Dunning MJ, Speed D, Lynch AG, Samarajiwa S, Yuan Y, Graf S, Ha G, Haffari G, Bashashati A, Russell R, McKinney S, Langerod A, Green A, Provenzano E, Wishart G, et al, (2012) The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups. Nature 486: 346-352
15. Davis PD, Elliott LH, Harris W, Hill CH, Hurst SA, Keech E, Kumar MK, Lawton G, Nixon JS, Wilkinson SE, (1992) Inhibitors of protein kinase C. 2. Substituted bisindolylmaleimides with improved potency and selectivity. J Med Chem 35: 994-1001
16. Dent R, Trudeau M, Pritchard KI, Hanna WM, Kahn HK, Sawka CA, Lickley LA, Rawlinson E, Sun P, Narod SA, (2007) Triple-negative breast cancer: clinical features and patterns of recurrence. Clin Cancer Res 13: 4429-4434
17. DeRose YS, Wang G, Lin YC, Bernard PS, Buys SS, Ebbert MT, Factor R, Matsen C, Milash BA, Nelson E, Neumayer L, Randall RL, Stijleman IJ, Welm BE, Welm AL, (2011) Tumor grafts derived from women with breast cancer authentically reflect tumor pathology, growth, metastasis and disease outcomes. Nat Med 17: 1514-1520
18. Diamond JR, Eckhardt SG, Tan AC, Newton TP, Selby HM, Brunkow KL, Kachaeva MI, Varella-Garcia M, Pitts TM, Bray MR, Fletcher GC, Tentler JJ, (2013) Predictive Biomarkers of Sensitivity to the Aurora and Angiogenic Kinase Inhibitor ENMD-2076 in Preclinical Breast Cancer Models. Clin Cancer Res 19: 291-303
19. Dolled-Filhart M, Camp RL, Kowalski DP, Smith BL, Rimm DL, (2003) Tissue microarray analysis of signal transducers and activators of transcription 3 (Stat3) and phospho-Stat3 (Tyr705) in node-negative breast cancer shows nuclear localization is associated with a better prognosis. Clin Cancer Res 9: 594-600
20. Ficarro SB, Zhang Y, Lu Y, Moghimi AR, Askenazi M, Hyatt E, Smith ED, Boyer L, Schlaeger TM, Luckey CJ, Marto JA, (2009) Improved electrospray ionization efficiency compensates for diminished chromatographic resolution and enables proteomics analysis of tyrosine signaling in embryonic stem cells. Anal Chem 81: 3440-3447
21. Fillmore CM, Kuperwasser C, (2008) Human breast cancer cell lines contain stem-like cells that self-renew, give rise to phenotypically diverse progeny and survive chemotherapy. Breast Cancer Res 10: R25
22. Fischer T, Stone RM, Deangelo DJ, Galinsky I, Estey E, Lanza C, Fox E, Ehninger G, Feldman EJ, Schiller GJ, Klimek VM, Nimer SD, Gilliland DG, Dutreix C, Huntsman-Labed A, Virkus J, Giles FJ, (2010) Phase IIB trial of oral Midostaurin (PKC412), the FMS-like tyrosine kinase 3 receptor (FLT3) and multi-targeted kinase inhibitor, in patients with acute myeloid leukemia and high-risk myelodysplastic syndrome with either wild-type or mutated FLT3. J Clin Oncol 28: 4339-4345
23. Friedberg JW, Sharman J, Sweetenham J, Johnston PB, Vose JM, Lacasce A, Schaefer-Cutillo J, De Vos S, Sinha R, Leonard JP, Cripe LD, Gregory SA, Sterba MP, Lowe AM, Levy R, Shipp MA, (2010) Inhibition of Syk with fostamatinib disodium has significant clinical activity in non-Hodgkin lymphoma and chronic lymphocytic leukemia. Blood 115: 2578-2585
24. Garcia R, Bowman TL, Niu G, Yu H, Minton S, Muro-Cacho CA, Cox CE, Falcone R, Fairclough R, Parsons S, Laudano A, Gazit A, Levitzki A, Kraker A, Jove R, (2001) Constitutive activation of Stat3 by the Src and JAK tyrosine kinases participates in growth regulation of human breast carcinoma cells. Oncogene 20: 2499-2513
25. Guiu S, Michiels S, Andre F, Cortes J, Denkert C, Di Leo A, Hennessy BT, Sorlie T, Sotiriou C, Turner N, Van de Vijver M, Viale G, Loi S, Reis-Filho JS, (2012) Molecular subclasses of breast cancer: how do we define them? The IMPAKT 2012 Working Group Statement. Ann Oncol 23: 2997-3006
26. Haffty BG, Yang Q, Reiss M, Kearney T, Higgins SA, Weidhaas J, Harris L, Hait W, Toppmeyer D, (2006) Locoregional relapse and distant metastasis in conservatively managed triple negative early-stage breast cancer. J Clin Oncol 24: 5652-5657
27. Hawkins PC, Skillman AG, Warren GL, Ellingson BA, Stahl MT, (2010) Conformer generation with OMEGA: algorithm and validation using high quality structures from the Protein Databank and Cambridge Structural Database. J Chem Inf Model 50: 572-584
28. Hawkins PC, Nicholls A, (2012) Conformer generation with OMEGA: learning from the data set and the analysis of failures. J Chem Inf Model 52: 2919-2936
29. Hennessy BT, Gonzalez-Angulo AM, Stemke-Hale K, Gilcrease MZ, Krishnamurthy S, Lee JS, Fridlyand J, Sahin A, Agarwal R, Joy C, Liu W, Stivers D, Baggerly K, Carey M, Lluch A, Monteagudo C, He X, Weigman V, Fan C, Palazzo J, et al, (2009) Characterization of a naturally occurring breast cancer subset enriched in epithelial-to-mesenchymal transition and stem cell characteristics. Cancer Res 69: 4116-4124
30. Honeth G, Bendahl PO, Ringner M, Saal LH, Gruvberger-Saal SK, Lovgren K, Grabau D, Ferno M, Borg A, Hegardt C, (2008) The CD44+/CD24- phenotype is enriched in basal-like breast tumors. Breast Cancer Res 10: R53
31. Huang S, (2011) Systems biology of stem cells: three useful perspectives to help overcome the paradigm of linear pathways. Philos Trans R Soc Lond B Biol Sci 366: 2247-2259
32. Humphreys RC, Bierie B, Zhao L, Raz R, Levy D, Hennighausen L, (2002) Deletion of Stat3 blocks mammary gland involution and extends functional competence of the secretory epithelium in the absence of lactogenic stimuli. Endocrinology 143: 3641-3650
33. Ibrahim YH, Garcia-Garcia C, Serra V, He L, Torres-Lockhart K, Prat A, Anton P, Cozar P, Guzman M, Grueso J, Rodriguez O, Calvo MT, Aura C, Diez O, Rubio IT, Perez J, Rodon J, Cortes J, Ellisen LW, Scaltriti M, et al, (2012) PI3K inhibition impairs BRCA1/2 expression and sensitizes BRCA-proficient triple-negative breast cancer to PARP inhibition. Cancer Discov 2: 1036-1047
34. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D, (2011) Global cancer statistics. CA Cancer J Clin 61: 69-90
35. Kohler S, Bauer S, Horn D, Robinson PN, (2008) Walking the interactome for prioritization of candidate disease genes. Am J Hum Genet 82: 949-958
36. Lage K, Hansen NT, Karlberg EO, Eklund AC, Roque FS, Donahoe PK, Szallasi Z, Jensen TS, Brunak S, (2008) A large-scale analysis of tissue-specific pathology and gene expression of human disease genes and complexes. Proc Natl Acad Sci USA 105: 20870-20875
37. Larive RM, Urbach S, Poncet J, Jouin P, Mascre G, Sahuquet A, Mangeat PH, Coopman PJ, Bettache N, (2009) Phosphoproteomic analysis of Syk kinase signaling in human cancer cells reveals its role in cell-cell adhesion. Oncogene 28: 2337-2347
38. Liu R, Wang X, Chen GY, Dalerba P, Gurney A, Hoey T, Sherlock G, Lewicki J, Shedden K, Clarke MF, (2007) The prognostic role of a gene signature from tumorigenic breast-cancer cells. N Engl J Med 356: 217-226
39. Marotta LL, Almendro V, Marusyk A, Shipitsin M, Schemme J, Walker SR, Bloushtain-Qimron N, Kim JJ, Choudhury SA, Maruyama R, Wu Z, Gonen M, Mulvey LA, Bessarabova MO, Huh SJ, Silver SJ, Kim SY, Park SY, Lee HE, Anderson KS, et al, (2011) The JAK2/STAT3 signaling pathway is required for growth of CD44(+)CD24(-) stem cell-like breast cancer cells in human tumors. J Clin Invest 121: 2723-2735
40. McGaughey GB, Sheridan RP, Bayly CI, Culberson JC, Kreatsoulas C, Lindsley S, Maiorov V, Truchon JF, Cornell WD, (2007) Comparison of topological, shape, and docking methods in virtual screening. J Chem Inf Model 47: 1504-1519
41. Monnerat C, Henriksson R, Le Chevalier T, Novello S, Berthaud P, Faivre S, Raymond E, (2004) Phase I study of PKC412 (N-benzoyl-staurosporine), a novel oral protein kinase C inhibitor, combined with gemcitabine and cisplatin in patients with non-small-cell lung cancer. Ann Oncol 15: 316-323
42. Neve RM, Chin K, Fridlyand J, Yeh J, Baehner FL, Fevr T, Clark L, Bayani N, Coppe JP, Tong F, Speed T, Spellman PT, DeVries S, Lapuk A, Wang NJ, Kuo WL, Stilwell JL, Pinkel D, Albertson DG, Waldman FM, et al, (2006) A collection of breast cancer cell lines for the study of functionally distinct cancer subtypes. Cancer Cell 10: 515-527
43. Oft M, Peli J, Rudaz C, Schwarz H, Beug H, Reichmann E, (1996) TGF-beta1 and Ha-Ras collaborate in modulating the phenotypic plasticity and invasiveness of epithelial tumor cells. Genes Dev 10: 2462-2477
44. Perou CM, Sorlie T, Eisen MB, van de Rijn M, Jeffrey SS, Rees CA, Pollack JR, Ross DT, Johnsen H, Akslen LA, Fluge O, Pergamenschikov A, Williams C, Zhu SX, Lonning PE, Borresen-Dale AL, Brown PO, Botstein D, (2000) Molecular portraits of human breast tumours. Nature 406: 747-752
45. Prat A, Parker JS, Karginova O, Fan C, Livasy C, Herschkowitz JI, He X, Perou CM, (2010) Phenotypic and molecular characterization of the claudin-low intrinsic subtype of breast cancer. Breast Cancer Res 12: R68
46. Propper DJ, McDonald AC, Man A, Thavasu P, Balkwill F, Braybrooke JP, Caponigro F, Graf P, Dutreix C, Blackie R, Kaye SB, Ganesan TS, Talbot DC, Harris AL, Twelves C, (2001) Phase I and pharmacokinetic study of PKC412, an inhibitor of protein kinase C. J Clin Oncol 19: 1485-1492
47. Rix U, Superti-Furga G, (2009) Target profiling of small molecules by chemical proteomics. Nat Chem Biol 5: 616-624
48. Romanelli A, Clark A, Assayag F, Chateau-Joubert S, Poupon MF, Servely JL, Fontaine JJ, Liu X, Spooner E, Goodstal S, de Cremoux P, Bieche I, Decaudin D, Marangoni E, (2012) Inhibiting aurora kinases reduces tumor growth and suppresses tumor recurrence after chemotherapy in patient-derived triple-negative breast cancer xenografts. Mol Cancer Ther 11: 2693-2703
49. Solimini NL, Luo J, Elledge SJ, (2007) Non-oncogene addiction and the stress phenotype of cancer cells. Cell 130: 986-988
50. Staff S, Isola J, Jumppanen M, Tanner M, (2010) Aurora-A gene is frequently amplified in basal-like breast cancer. Oncol Rep 23: 307-312
51. Sung YM, Xu X, Sun J, Mueller D, Sentissi K, Johnson P, Urbach E, Seillier-Moiseiwitsch F, Johnson MD, Mueller SC, (2009) Tumor suppressor function of Syk in human MCF10A in vitro and normal mouse mammary epithelium in vivo. PLoS One 4: e7445
52. TCGA (2012) Comprehensive molecular portraits of human breast tumours. Nature 490: 61-70
53. Turner M, Schweighoffer E, Colucci F, Di Santo JP, Tybulewicz VL, (2000) Tyrosine kinase SYK: essential functions for immunoreceptor signalling. Immunol Today 21: 148-154
54. Vesuna F, Lisok A, Kimble B, Raman V, (2009) Twist modulates breast cancer stem cells by transcriptional regulation of CD24 expression. Neoplasia 11: 1318-1328
55. Zhang X, Shrikhande U, Alicie BM, Zhou Q, Geahlen RL, (2009) Role of the protein tyrosine kinase Syk in regulating cell-cell adhesion and motility in breast cancer cells. Mol Cancer Res 7: 634-644